Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 325 | 0.91 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 5820
Sealed predictions
- NFIX in dopamine neurons, braak-0.56 (p 0.118) → -0.18 (p 0.635)receipt 5826
Swarm cases
receipt 5826: NFIX in dopamine neurons, braak
- power
- full sample -0.38 (p 0.116, n 18), 95% CI -0.72 to +0.10. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.39 (p 0.105, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.46 (p 0.056, n 18). could be the mix.
- skeptic
- leave-one-out range -0.53 to -0.30, sign flips 0; without severely affected donors -0.38 (p 0.116, n 18). fragile.
- cell type
- strongest in microglia: -0.63 (p 0.0055, n 18) vs -0.38 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NFIX in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up NFIX · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.70 p 0.013 (needs p < 3.4e-4)
Receipts
loading the receipts